Patent ID: 7718192

Claim:
A composition comprising an opioid antagonist and from about 93% to about 98% of a hydrophobic material by weight of the composition, with the proviso that the composition does not comprise an opioid agonist, wherein the hydrophobic material sequesters the antagonist such that, upon inclusion into a solid oral dosage form containing an opioid agonist, an amount of the antagonist released from said dosage form which has been orally administered intact is less than an amount bioequivalent to 0.125 mg of naltrexone, based on the in-vitro dissolution at 1 hour of the dosage form in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37° C., and is insufficient to produce an antagonist effect of the antagonist, but an amount of the antagonist released from said dosage form which has been tampered with and administered orally, intranasally, parenterally or sublingually is bioequivalent to 0.25 mg of naltrexone or more, based on the in-vitro dissolution at 1 hour of the dosage form in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37° C., and will substantially block an effect of the agonist; the intact dosage form releasing less than 15% by weight of the opioid antagonist within 36 hours, based on the in-vitro dissolution in a dissolution bath, wherein the antagonist is dispersed in a matrix of said hydrophobic material.